P/E ratio for Astellas Pharma (4503.T)
P/E ratio as of April 2024 (TTM): 22.9
According to Astellas Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.9272. At the end of 2022 the company had a P/E ratio of 26.7.
P/E ratio history for Astellas Pharma from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 26.7 | -7.23% |
| 2021 | 28.8 | 35.18% |
| 2020 | 21.3 | 33.87% |
| 2019 | 15.9 | 25.14% |
| 2018 | 12.7 | -20.92% |
| 2017 | 16.1 | -2.61% |
| 2016 | 16.5 | -18.25% |
| 2015 | 20.2 | -33.74% |
| 2014 | 30.5 | 103.23% |
| 2013 | 15.0 | -45.73% |
| 2012 | 27.7 | 66.7% |
| 2011 | 16.6 | -0.5% |
| 2010 | 16.7 | 35.86% |
| 2009 | 12.3 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.